Identification

Name
Prazepam
Accession Number
DB01588
Type
Small Molecule
Groups
Approved, Illicit
Description

Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.

Structure
Thumb
Synonyms
  • Prazepamum
External IDs
W 4020
International/Other Brands
Centrax / Demetrin / Lysanxia / Sedapran / Trepidan
Categories
UNII
Q30VCC064M
CAS number
2955-38-6
Weight
Average: 324.804
Monoisotopic: 324.102940883
Chemical Formula
C19H17ClN2O
InChI Key
MWQCHHACWWAQLJ-UHFFFAOYSA-N
InChI
InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
IUPAC Name
7-chloro-1-(cyclopropylmethyl)-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1

Pharmacology

Indication

For the treatment of anxiety disorders.

Structured Indications
Not Available
Pharmacodynamics

Prazepam is a benzodiazepine derivative drug. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses.

Mechanism of action

Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit delta
potentiator
Human
AGamma-aminobutyric acid receptor subunit epsilon
potentiator
Human
AGamma-aminobutyric acid receptor subunit pi
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-3
potentiator
Human
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

36-200 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Prazepam is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Prazepam is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Prazepam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Prazepam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Prazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Prazepam.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Prazepam is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Prazepam.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Prazepam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prazepam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Prazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental
AminophyllineThe therapeutic efficacy of Prazepam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Prazepam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Prazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Prazepam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Prazepam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Prazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Prazepam is combined with Amperozide.Experimental
AprepitantThe serum concentration of Prazepam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Prazepam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Prazepam.Approved
AtazanavirThe metabolism of Prazepam can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Prazepam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Azaperone.Vet Approved
AzelastinePrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Prazepam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Prazepam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Prazepam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Prazepam.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Prazepam is combined with Benzyl alcohol.Approved
BoceprevirThe metabolism of Prazepam can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Prazepam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Prazepam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Prazepam is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Prazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Prazepam is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Prazepam is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Prazepam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazepam.Approved, Investigational
BuprenorphinePrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Prazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Prazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Prazepam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Prazepam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Prazepam.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Prazepam is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Prazepam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Prazepam.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Prazepam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Prazepam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Prazepam.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Prazepam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Prazepam.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Prazepam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prazepam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Prazepam.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Prazepam.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram.Approved
ClarithromycinThe metabolism of Prazepam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Prazepam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Prazepam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Prazepam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Prazepam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Prazepam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Prazepam is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Prazepam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Prazepam is combined with Clozapine.Approved
CobicistatThe metabolism of Prazepam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Prazepam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Prazepam.Approved, Illicit
ConivaptanThe serum concentration of Prazepam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Prazepam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prazepam.Approved
CyclosporineThe metabolism of Prazepam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Prazepam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Prazepam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prazepam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Prazepam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Prazepam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Prazepam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Prazepam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Prazepam can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Prazepam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Prazepam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Prazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Prazepam.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Prazepam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prazepam.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Prazepam.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Prazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Prazepam is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Prazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prazepam.Approved, Illicit
DihydroergotamineThe metabolism of Prazepam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Prazepam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Prazepam.Experimental, Illicit
DiltiazemThe metabolism of Prazepam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Prazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Prazepam.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prazepam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Prazepam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Prazepam is combined with Doxepin.Approved
DoxycyclineThe metabolism of Prazepam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Prazepam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
DronedaroneThe metabolism of Prazepam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Prazepam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Prazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam.Approved
DyphyllineThe therapeutic efficacy of Prazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Prazepam.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Prazepam is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Prazepam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Prazepam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Prazepam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Prazepam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Prazepam can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Prazepam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prazepam.Approved
EthanolPrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prazepam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Prazepam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Prazepam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Prazepam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Prazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Prazepam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Prazepam.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Prazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Prazepam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Prazepam.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Prazepam is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Prazepam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Prazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Prazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Prazepam.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Prazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Prazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Prazepam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Prazepam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Prazepam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Prazepam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Prazepam is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Prazepam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Prazepam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Prazepam is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Prazepam.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Prazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Prazepam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Prazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Prazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Prazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Prazepam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Prazepam.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Prazepam.Approved
HyaluronidaseThe therapeutic efficacy of Prazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodonePrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved
IdelalisibThe serum concentration of Prazepam can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Iloperidone.Approved
ImatinibThe metabolism of Prazepam can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Prazepam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Prazepam can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Prazepam is combined with Indiplon.Investigational
IsavuconazoniumThe metabolism of Prazepam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Prazepam.Approved, Vet Approved
IsradipineThe metabolism of Prazepam can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Prazepam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Prazepam can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Prazepam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Prazepam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Prazepam can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Prazepam is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Prazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Prazepam.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Prazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Prazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Prazepam.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Prazepam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Prazepam.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Prazepam.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Prazepam.Approved
LofentanilThe risk or severity of adverse effects can be increased when Prazepam is combined with Lofentanil.Illicit
LopinavirThe metabolism of Prazepam can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Prazepam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Prazepam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Lormetazepam.Approved
LovastatinThe metabolism of Prazepam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Prazepam.Approved
LuliconazoleThe serum concentration of Prazepam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Prazepam can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Prazepam.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Prazepam is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Prazepam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Prazepam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Prazepam.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prazepam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Prazepam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Prazepam.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Prazepam is combined with Metaxalone.Approved
MethadonePrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Prazepam.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Prazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Prazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Prazepam.Approved
MethotrimeprazinePrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Prazepam.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Prazepam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Prazepam is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Prazepam.Approved
MetyrosinePrazepam may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Prazepam.Approved, Illicit
MifepristoneThe serum concentration of Prazepam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Prazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Investigational
MirtazapinePrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Prazepam can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Prazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Prazepam.Approved
NefazodoneThe metabolism of Prazepam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Prazepam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Prazepam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Prazepam can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Prazepam can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Prazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Prazepam.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Prazepam is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Prazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Prazepam.Approved, Investigational
OlaparibThe metabolism of Prazepam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Prazepam.Approved
OpiumThe risk or severity of adverse effects can be increased when Prazepam is combined with Opium.Approved, Illicit
OrphenadrinePrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Prazepam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Prazepam can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Prazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Prazepam.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Prazepam.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Prazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Prazepam.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Prazepam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Prazepam.Approved
ParaldehydePrazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Prazepam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prazepam.Approved, Vet Approved
PentobarbitalThe metabolism of Prazepam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Prazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Prazepam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Prazepam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Prazepam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Prazepam is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Prazepam can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Prazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Prazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Prazepam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Prazepam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Prazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Prazepam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Prazepam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePrazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Pramocaine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Prazepam.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Prazepam.Approved
PrimidoneThe metabolism of Prazepam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Prazepam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Prazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Prazepam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Prazepam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Prazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Prazepam is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Prazepam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Prazepam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Prazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Prazepam.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Prazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Prazepam is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Prazepam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prazepam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prazepam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prazepam.Approved
RifabutinThe metabolism of Prazepam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Prazepam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Prazepam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Prazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Prazepam is combined with Ritanserin.Investigational
RitonavirThe metabolism of Prazepam can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Romifidine.Vet Approved
RopinirolePrazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazepam.Approved
RotigotinePrazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Prazepam.Approved
SaquinavirThe metabolism of Prazepam can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prazepam.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Prazepam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Prazepam is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Prazepam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Prazepam.Approved, Vet Approved
SildenafilThe metabolism of Prazepam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Prazepam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Prazepam can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Prazepam can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Prazepam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam.Approved, Investigational
SulfisoxazoleThe metabolism of Prazepam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prazepam.Approved
SultoprideThe risk or severity of adverse effects can be increased when Prazepam is combined with Sultopride.Experimental
SuvorexantPrazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Prazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Prazepam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Prazepam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Prazepam can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Prazepam can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Prazepam.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrodotoxin.Investigational
ThalidomidePrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Prazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Prazepam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Prazepam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Prazepam.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Prazepam.Approved
TiagabineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Prazepam is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Prazepam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Prazepam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Prazepam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Prazepam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Prazepam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prazepam.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Prazepam.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Prazepam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Prazepam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Prazepam is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prazepam.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Prazepam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Prazepam.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Prazepam.Approved, Investigational
VenlafaxineThe metabolism of Prazepam can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Prazepam is combined with Veralipride.Experimental
VerapamilThe metabolism of Prazepam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Prazepam is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Prazepam is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Prazepam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Prazepam is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Prazepam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Prazepam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Prazepam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Prazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Prazepam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Zolazepam.Vet Approved
ZolpidemPrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Prazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Prazepam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Prazepam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Prazepam.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid taking with grapefruit juice.
  • Take with food.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15527
KEGG Drug
D00470
KEGG Compound
C07366
PubChem Compound
4890
PubChem Substance
46505417
ChemSpider
4721
ChEBI
8362
ChEMBL
CHEMBL969
Therapeutic Targets Database
DAP000689
PharmGKB
PA164776668
Wikipedia
Prazepam
ATC Codes
N05BA11 — Prazepam

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
Not Available
Prices
Unit descriptionCostUnit
Doral 15 mg tablet3.41USD tablet
Doral 7.5 mg tablet3.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)145-146 °CPhysProp
logP3.73HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00399 mg/mLALOGPS
logP3.68ALOGPS
logP3.86ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)3.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.67 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity91.75 m3·mol-1ChemAxon
Polarizability34.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9821
Blood Brain Barrier+0.9934
Caco-2 permeable+0.6922
P-glycoprotein substrateSubstrate0.6631
P-glycoprotein inhibitor IInhibitor0.7452
P-glycoprotein inhibitor IIInhibitor0.6438
Renal organic cation transporterInhibitor0.6625
CYP450 2C9 substrateNon-substrate0.7317
CYP450 2D6 substrateNon-substrate0.8332
CYP450 3A4 substrateSubstrate0.7471
CYP450 1A2 substrateInhibitor0.861
CYP450 2C9 inhibitorInhibitor0.5153
CYP450 2D6 inhibitorNon-inhibitor0.7477
CYP450 2C19 inhibitorInhibitor0.7793
CYP450 3A4 inhibitorInhibitor0.6455
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7974
Ames testNon AMES toxic0.8623
CarcinogenicityNon-carcinogens0.8138
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8779 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9819
hERG inhibition (predictor II)Non-inhibitor0.5471
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-00r5-3391000000-0113e86cca51d223d412
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives / Benzene and substituted derivatives / Aryl chlorides / Tertiary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organochlorides
show 3 more
Substituents
1,4-benzodiazepine / Alpha-amino acid or derivatives / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Tertiary carboxylic acid amide / Carboxamide group / Ketimine / Lactam
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzodiazepine (CHEBI:8362)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Amin J, Brooks-Kayal A, Weiss DS: Two tyrosine residues on the alpha subunit are crucial for benzodiazepine binding and allosteric modulation of gamma-aminobutyric acidA receptors. Mol Pharmacol. 1997 May;51(5):833-41. [PubMed:9145922]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG1
Uniprot ID
Q8N1C3
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-1
Molecular Weight
53594.49 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRG2
Uniprot ID
P18507
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-2
Molecular Weight
54161.78 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG3
Uniprot ID
Q99928
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-3
Molecular Weight
54288.16 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB1
Uniprot ID
P18505
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-1
Molecular Weight
54234.085 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB2
Uniprot ID
P47870
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight
59149.895 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-gated chloride ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB3
Uniprot ID
P28472
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-3
Molecular Weight
54115.04 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRD
Uniprot ID
O14764
Uniprot Name
Gamma-aminobutyric acid receptor subunit delta
Molecular Weight
50707.835 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRE
Uniprot ID
P78334
Uniprot Name
Gamma-aminobutyric acid receptor subunit epsilon
Molecular Weight
57971.175 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
Gene Name
GABRP
Uniprot ID
O00591
Uniprot Name
Gamma-aminobutyric acid receptor subunit pi
Molecular Weight
50639.735 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
Gene Name
GABRR1
Uniprot ID
P24046
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-1
Molecular Weight
55882.91 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
Gene Name
GABRR2
Uniprot ID
P28476
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-2
Molecular Weight
54150.41 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRR3
Uniprot ID
A8MPY1
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-3
Molecular Weight
54271.1 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on August 29, 2007 09:29 / Updated on October 02, 2017 05:00